MR-based follow-up after brachytherapy and proton beam therapy in uveal melanoma
Open Access
- 30 May 2023
- journal article
- research article
- Published by Springer Nature in Neuroradiology
- Vol. 65 (8) , 1271-1285
Abstract
Purpose: MRI is increasingly used in the diagnosis and therapy planning of uveal melanoma (UM). In this prospective cohort study, we assessed the radiological characteristics, in terms of anatomical and functional imaging, of UM after ruthenium-106 plaque brachytherapy or proton beam therapy (PBT) and compared them to conventional ultrasound. Methods: Twenty-six UM patients were evaluated before and 3, 6 and 12 months after brachytherapy (n = 13) or PBT (n = 13). Tumour prominences were compared between ultrasound and MRI. On diffusion-weighted imaging, the apparent diffusion value (ADC), and on perfusion-weighted imaging (PWI), the time-intensity curves (TIC), relative peak intensity and outflow percentages were determined. Values were compared between treatments and with baseline. Results: Pre-treatment prominences were comparable between MRI and ultrasound (mean absolute difference 0.51 mm, p = 0.46), but larger differences were observed post-treatment (e.g. 3 months: 0.9 mm (p = 0.02)). Pre-treatment PWI metrics were comparable between treatment groups. After treatment, brachytherapy patients showed favourable changes on PWI (e.g. 67% outflow reduction at 3 months, p < 0.01). After PBT, significant perfusion changes were observed at a later timepoint (e.g. 38% outflow reduction at 6 months, p = 0.01). No consistent ADC changes were observed after either treatment, e.g. a 0.11 × 10−3mm2/s increase 12 months after treatment (p = 0.15). Conclusion: MR-based follow-up is valuable for PBT-treated patients as favourable perfusion changes, including a reduction in outflow, can be detected before a reduction in size is apparent on ultrasound. For brachytherapy, a follow-up MRI is of less value as already 3 months post-treatment a significant size reduction can be measured on ultrasound.Keywords
Funding Information
- KWF Kankerbestrijding (2019: 12184)
This publication has 49 references indexed in Scilit:
- Assessment of dynamic contrast-enhanced magnetic resonance imaging in the differentiation of malignant from benign orbital massesEuropean Journal of Radiology, 2013
- Diffusion-Weighted Imaging of Orbital Masses: Multi-Institutional Data Support a 2-ADC Threshold Model to Categorize Lesions as Benign, Malignant, or IndeterminateAmerican Journal of Neuroradiology, 2013
- Guidelines for imaging retinoblastoma: imaging principles and MRI standardizationPediatric Radiology, 2011
- On the scope and interpretation of the Tofts models for DCE‐MRIMagnetic Resonance in Medicine, 2011
- Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall SurvivalJournal of Clinical Oncology, 2008
- Tumour Regression of Uveal Melanoma after Ruthenium-106 Brachytherapy or Stereotactic Radiotherapy with Gamma Knife or Linear AcceleratorOphthalmologica, 2003
- The COMS randomized trial of iodine 125 brachytherapy for choroidal melanomaOphthalmology, 2002
- Design and methods of a clinical trial for a rare condition: The collaborative ocular melanoma studyControlled Clinical Trials, 1993
- Management of posterior uveal melanomaSurvey of Ophthalmology, 1991
- Standardized EchographyInternational Ophthalmology Clinics, 1979